Teva files Form 144 reporting RSU vesting and sales

Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed and recent ordinary share activity.

Accepted by SEC EDGAR 03/05/2026 - 05:32 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed and recent ordinary share activity. The filing lists 17,819 ordinary shares tied to a restricted share unit award vesting on 03/05/2026 through Citigroup Global Markets Inc. It also reports 9,908 ordinary shares sold on 03/04/2026 for $321,658.26.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TEVA's Form 144 show about the RSU vesting?

The Form 144 lists 17,819 ordinary shares tied to a restricted share unit award vesting on 03/05/2026. The filing names Citigroup Global Markets Inc. as the broker handling the listed securities.

How many TEVA shares were reported sold in the past three months?

The filing reports 9,908 ordinary shares sold on 03/04/2026. The sale proceeds shown for that transaction equal $321,658.26, and the seller is identified as Christine Fox in the excerpt.

Which broker is listed on the TEVA Form 144?

The Form 144 names Citigroup Global Markets Inc. with address 390 Greenwich Street, New York, NY 10013 as the broker associated with the securities to be sold and listed in the filing.

Does the Form 144 identify the transaction type for the listed shares?

Yes. The excerpt labels the 17,819-share entry as COMPENSATION tied to restricted share unit vesting, and the prior sale of 9,908 shares is recorded under the section for securities sold during the past 3 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001998173
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Fox Christine
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EVP HEAD OF US COMMERCIAL

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	7924	250940.40	1149812898	03/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/05/2025	RESTRICTED SHARE UNIT AWARD VESTING EM	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			17819	03/05/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Fox Christine 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/04/2026	9908	321658.26

144: Remarks and Signature

Remarks	SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES. THE SALES WERE PERFORMED UNDER AN ESTABLISHED 10B51 PLAN ADOPTED IN AUGUST 2025
Date of Notice	03/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)